News

Weiner joins DILIsym Services, Inc. Board of Directors

DILIsym Services, Inc. announces the appointment of Dr. Daniel Weiner as an independent Director to the Board of Directors of DILIsym Services, Inc.  Dr. Weiner joins recently appointed Directors, Dr. Brett Howell (Chief Executive Officer of DILsym Services, Inc.) and Dr. Scott Siler (President of DILIsym Services, Inc.). Dr. Weiner has extensive experience in both drug development and pharmacokinetic modeling, and was the original developer of WinNonlin and the co-designer of Trial Simulator which at the time was the first widely used commercial software designed for in-silico PKPD modeling. He was one of the early advocates for the use of in-silico approaches to improve trial design.  Dr. Weiner held several management positions with Certara/Pharsight;  Merrell Dow Pharmaceuticals; Statistical Consultants, Inc.; Syntex Development Research; Quintiles; and IVAX Research.

I am delighted to welcome Dan to our Board, and we are confident that his experience, extraordinary business and technology expertise, industry insights, and leadership qualities will prove invaluable as we continue to grow DILIsym Services, Inc.,” said Paul Watkins, MD, Chair of the Board of Directors of DILIsym Services, Inc. 

The DILIsym Services, Inc. Board of Directors currently has five members.